Today, as part of a national initiative funded by The John A. Hartford Foundation (JAHF), the national, independent nonprofit FAIR Health launched a new shared decision-making tool for Alzheimer's ...

Retired electrician Joe Walsh in December became the first Alzheimer’s patient to try a nasal spray used to treat other ...

Explore the potential of monoclonal antibodies in Alzheimer’s treatment, including breakthroughs and challenges in this ...

Some two years into Leqembi’s launch, Eisai continues to go all-in on its Alzheimer’s disease-fighting antibody, which the ...

Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal ...

The first drug proven to slow down Alzheimer's won't be available to dementia patients in Scotland - unless they pay £60,000 ...

Nearly every disease has an inflammatory component, but blood tests can't pinpoint inflammation in specific organs or tissues in the human body. Now researchers have developed a method to detect ...

Science X is a network of high quality websites with most complete and comprehensive daily coverage of the full sweep of ...

Nearly every disease has an inflammatory component, but blood tests can't pinpoint inflammation in specific organs or tissues ...

Children who inherit genetic mutations from parents with early-onset Alzheimer’s typically show signs of dementia at the same ...

Scientists are testing an experimental anti-amyloid antibody in people expected to develop early-onset Alzheimer's.

Readers worry that fraud may tarnish the field and slow the race for a cure. Also: Charles Blow’s farewell; treatment for ...